Get started
Author

Dheepak Kanagavel

Observed names: D Kanagavel, D. Kanagavel, Kanagavel, Dheepak
ORCID: 0000-0002-7684-8580
Observed ORCID: 0000-0002-7684-8580
OpenAlex ID: A5037865295
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
2019 · Joseph Mikhael, Paul Richardson, et al. · Blood · 90
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy
2010 · D. Kanagavel, I.A. Pokataev, et al. · Annals of Oncology · 63
Second-line treatment of metastatic gastric cancer: Current options and future directions
2015 · Dheepak Kanagavel · World Journal of Gastroenterology · 40
PDF
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
2022 · Aditya Bardia, Javier Cortes, et al. · Therapeutic Advances in Medical Oncology · 29
PDF
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5
2024 · Javier Cortés, Sara A. Hurvitz, et al. · Journal of Clinical Oncology · 22
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
2021 · Saad Z. Usmani, Chatchada Karanes, et al. · Leukemia · 22
PDF
Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
2018 · Enrique M. Ocio, Paula Rodriguez Otero, et al. · Blood · 22
Paclitaxel + BEP (T-BEP) Regimen as Induction Chemotherapy in Poor Prognosis Patients With Nonseminomatous Germ Cell Tumors: A Phase II Study
2011 · A. Tryakin, M. Fedyanin, et al. · Urology · 12
A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation
2017 · Enrique M. Ocio, Sara Bringhen, et al. · Blood · 10
Ps1390 Preliminary Data: Phase 1b Study of Feasibility/safety of Isatuximab Short Duration Fixed Volume Infusion in Combination With Pomalidomide and Dexamethasone for Relapsed/refractory Multiple Myeloma
2019 · S. Usmani, C. Karanes, et al. · HemaSphere · 5
Late relapses (>2 years) in patients with stage I testicular germ cell tumors: Predictive factors and survival
2011 · Mikhail Fedyanin, Alexey Tryakin, et al. · Urologic Oncology Seminars and Original Investigations · 5
MM-096: Isatuximab Short-Duration Fixed-Volume Infusion Combination Therapy for Relapsed/Refractory Multiple Myeloma: Final Results of a Phase 1b Feasibility/Safety Study
2020 · Saad Usmani, Chatchada Karanes, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
2017 · Paul G. Richardson, Joseph Mıkhael, et al. · Blood · 4
An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
2024 · Prashant Kapoor, Nitya Nathwani, et al. · European Journal Of Haematology · 2
PDF
AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.
2021 · Aditya Bardia, Javier Cortes, et al. · Journal of Clinical Oncology · 2
Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study
2019 · Saad Usmani, Chatchada Karanes, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
[Docetaxel in the treatment of metastatic gastric cancer].
2009 · I S Bazin, D Kanagavel, et al. · PubMed · 1
[Targeted drugs for the treatment of disseminated colonic cancer].
2009 · A M Garin, I S Bazin, et al. · PubMed · 1
PA-252 Incidence and Baseline Predictors of Venous Thromboembolism in Isa-VRd and VRd Arms of the Phase 3 IMROZ Trial in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma (Ti NDMM)
2026 · Emilie Chalayer, Muhamad Baljevic, et al. · Clinical Lymphoma Myeloma & Leukemia
Clonotypic peptide mass spectrometry to monitor m-protein reduction in patients with relapsed/refractory multiple myeloma from ikema Study
2025 · Luciano Di Stefano, Victor Vimard, et al. · Blood
PDF
First-in-Human, Open-Label, Phase 1 Trial Design of SAR446523, a Novel Anti-GPRC5D Antibody-Dependent Cellular Cytotoxicity (ADCC)-Enhanced Monoclonal Antibody for Multiple Myeloma
2025 · Prashant Kapoor, Sikander Ailawadhi, et al. · Clinical Lymphoma Myeloma & Leukemia
Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer
2022 · Aditya Bardia, Javier Cortes, et al. · Cancer Research
Combination of docetaxel, cisplatin, and capecitabine (DCX) as a first-line chemotherapy in patients with metastatic gastric carcinoma: A phase II study.
2012 · Mekhty Narimanov, Alexey Tryakin, et al. · Journal of Clinical Oncology
Complete disappearance of retroperitoneal lymph nodes after induction chemotherapy in advanced nonseminomatous germ cell tumors (NSGCT): Is there a place for adjunctive surgery?
2012 · Alexey Tryakin, Mikhail Fedyanin, et al. · Journal of Clinical Oncology
7166 POSTER Validation of the Prognostic Score System for Survival in Patients (pts) With Relapses of Metastatic Nonseminomatous Germ Cell Tumours (mNGCT) After Induction Chemotherapy (iCT)
2011 · M. Fedianin, A. Tryakin, et al. · European Journal of Cancer
Works count: 33
Citation count: 336
H-index: 9
I10-index: 9
Year
Topic
Type